Skip to content
Sulfadiazine, silver
Silvadene, Ssd, Thermazene (sulfadiazine, silver) is a small molecule pharmaceutical. Sulfadiazine, silver was first approved as Silvadene on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Silvadene, Ssd, Thermazene (discontinued: Sildaflo)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Silver sulfadiazine
Tradename
Company
Number
Date
Products
SSDDr Reddys LaboratoriesN-018578 RX1982-02-25
1 products
SILVADENEKing PharmaceuticalsN-017381 RX1982-01-01
1 products, RLD, RS
THERMAZENEThe Pharma NetworkN-018810 RX1985-12-23
1 products
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
silvadeneNew Drug Application2022-05-09
silver sulfadiazineNew Drug Application2023-06-07
thermazeneNew Drug Application2021-09-14
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BA: Sulfonamides, topical
— D06BA01: Silver sulfadiazine
— D06BA51: Silver sulfadiazine, combinations
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.925118429
Polycystic ovary syndromeD011085EFO_0000660E28.2———2—2
HypertensionD006973EFO_0000537I10——11—2
BulimiaD002032F50.2———112
Obstructive sleep apneaD020181EFO_0003918G47.33———1—1
SchizophreniaD012559EFO_0000692F20———1—1
Psychotic disordersD011618F20.81———1—1
Bipolar disorderD001714EFO_0000289F30.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177E66.3—21——3
Weight lossD015431HP_0001824——2——2
AsthmaD001249EFO_0000270J45——1——1
Binge-eating disorderD056912F50.2——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98————11
Heart diseasesD006331EFO_0003777I51.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSULFADIAZINE, SILVER
INN—
Description
Silver(1+) sulfadiazinate is a silver salt, a sulfonamidate and a member of pyrimidines. It has a role as an antimicrobial agent and an antibacterial drug. It contains a sulfadiazinate.
Classification
Small molecule
Drug classantimicrobials (sulfonamides derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+]
Identifiers
PDB—
CAS-ID22199-08-2
RxCUI9793
ChEMBL IDCHEMBL1382627
ChEBI ID9142
PubChem CID441244
DrugBankDB05245
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,311 adverse events reported
View more details